SUBSCRIBE
SUBSCRIBE

Phase I

Drug Development
Ziopharm Phase I Trial Yields Positive Results for Treatment of rGBM
The main Phase I monotherapy study had a favorable safety profile, showing that Ad+V was safely administered and tolerably in both craniotomy and stereotactic subjects.
May 29, 2020
 · 
3 min read
 · 
Krystle Vermes
Drug Development
Allogene’s ALLO-501 Shows Positive Results in Its Phase I ALPHA Trial
The data, which was presented at the American Society of Clinical Oncology annual meeting, looked into the use of ALLO-501 for relapsed/refractory non-Hodgkin lymphoma.
May 29, 2020
 · 
3 min read
 · 
Krystle Vermes
BioForest
Clinical Catch-Up: May 25-29
In the lead-up to the ASCO Annual Meeting, companies were presenting some of their trial data, while other companies were presenting news related to COVID-19 studies. Here’s a look.
May 29, 2020
 · 
10 min read
 · 
Mark Terry
Drug Development
Biopharma Update on the Novel Coronavirus: June 1
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 1, 2020.
May 28, 2020
 · 
3 min read
 · 
BioSpace Editorial Staff
Drug Development
Biopharma Update on the Novel Coronavirus: May 29
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 29, 2020.
May 28, 2020
 · 
2 min read
 · 
BioSpace Editorial Staff
Policy
Biopharma Update on the Novel Coronavirus: May 28
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 28, 2020.
May 28, 2020
 · 
6 min read
 · 
BioSpace Editorial Staff
Policy
Biopharma Update on the Novel Coronavirus: May 27
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 27, 2020.
May 27, 2020
 · 
4 min read
 · 
BioSpace Editorial Staff
Drug Development
CEPI-Backed Novavax Doses First Patients with COVID-19 Vaccine Candidate
The Maryland-based company has enrolled and dosed its first patients in a Phase I/II study.
May 26, 2020
 · 
3 min read
 · 
Alex Keown
Drug Development
Biopharma Update on the Novel Coronavirus: May 26
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 26, 2020.
May 26, 2020
 · 
4 min read
 · 
BioSpace Editorial Staff
Drug Development
CanSino Publishes Phase I Data for COVID-19 Vaccine Candidate, Moves into Phase II
A COVID-19 vaccine candidate under development by China’s CanSino Biologics is moving forward in development after the company published data supporting its safety in patients.
May 22, 2020
 · 
2 min read
 · 
Alex Keown
Load More
PRESS RELEASES
Drug Development
IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual Meeting
May 23, 2024
 · 
6 min read
Drug Development
Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
May 23, 2024
 · 
8 min read
Drug Development
Tizona Therapeutics Presents Phase 1b TTX-080 Clinical Data in Advanced Colorectal Cancer and Head and Neck Squamous Cell Carcinoma at ASCO 2024
May 23, 2024
 · 
5 min read
Drug Development
Biomica Presents Positive Clinical Data Update from Ongoing Phase 1 Trial of Microbiome-Based Therapeutic, BMC128, for Refractory RCC, NSCLC & Melanoma
May 23, 2024
 · 
9 min read
Drug Development
Mythic Therapeutics to Present Data from Phase 1 KisMET-01 Study on MYTX-011 at the American Society of Clinical Oncology (ASCO) Annual Meeting
May 23, 2024
 · 
2 min read
Drug Development
iCell Gene Therapeutics Announces Positive Clinical Data from Investigator Initiated Phase 1 Trial Evaluating BCMA-CD19 Compound CAR in Patients with Systemic Lupus Erythematosus
May 23, 2024
 · 
6 min read
Drug Development
Protagenic Therapeutics’ Stress-Regulating Peptide Demonstrates Exceptional Safety in Single Dose Portion of Phase I Trial, Paving the Way for Next Steps Toward Potential Breakthrough Treatments in Stress Related Neuropsychiatric Disorders
May 22, 2024
 · 
2 min read
Drug Development
Inipharm to Present Pharmacokinetic Data From a Phase 1 Clinical Trial of INI-822, a Small Molecule Inhibitor of HSD17B13
May 22, 2024
 · 
3 min read
Drug Development
Indaptus Therapeutics Announces Completion of First Patient to Receive Multiple Doses of Decoy20, the Company’s Broad-Based, “Pulse-Prime” Immuno-Oncology Therapy for Advanced Solid Tumors
May 22, 2024
 · 
8 min read
Drug Development
IRLAB has Administered the First Dose in a Phase I Clinical Trial with the Drug Candidate IRL757
May 22, 2024
 · 
5 min read
Drug Development
Eupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
May 21, 2024
 · 
9 min read
Drug Development
Kinaset Therapeutics Debuts Positive Outcomes Data from Phase 1b Study of KN-002 at the 2024 American Thoracic Society (ATS) International Conference
May 21, 2024
 · 
5 min read
Drug Development
Anixa Biosciences Commences Treatment of Fifth Patient in Ovarian Cancer CAR-T Clinical Trial
May 21, 2024
 · 
4 min read
Drug Development
Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target
May 20, 2024
 · 
11 min read
Drug Development
Rila Therapeutics Announces Dosing of First Cohort in Phase 1 Clinical Trial of RLA-23174, a First-In-Class HIPK2 Allosteric Inhibitor, For Treatment of Chronic Kidney Disease and Fibrosis
May 20, 2024
 · 
3 min read
Business
Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics’ COVID-19 Vaccine
May 20, 2024
 · 
6 min read
Drug Development
Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics’ COVID-19 Vaccine
May 20, 2024
 · 
6 min read
Drug Development
Kiromic BioPharma Adds UPMC as Fourth Deltacel-01 Clinical Trial Site
May 20, 2024
 · 
6 min read
Drug Development
Anokion Announces New Clinical Data from the Phase 1b/2 ACeD-it Trial Supporting KAN-101 as a Potential Disease-Modifying Treatment for Celiac Disease
May 20, 2024
 · 
3 min read
Drug Development
GigaGen Doses First Patient in Phase 1 Trial of Anti-CTLA-4 Oncology Drug Candidate GIGA-564 in Advanced Solid Tumors
May 20, 2024
 · 
6 min read
Load More